Bulletin
Investor Alert

April 21, 2021, 7:15 p.m. EDT

Non-Small Cell Lung Cancer Competitive Landscape 2020: Emerging Therapies and Key pharma players involved by DelveInsight

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 21, 2021 (AB Digital via COMTEX) -- DelveInsight’s, “Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insights, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.

Click here to read more.

The three main histological subtypes of Non-Small Cell Lung Cancer are:

  • Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.

  • Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.

  • Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.

Read more about the Non-small Cell lung cancer pipeline report .

NSCLC Emerging Therapies:

  • Canakinumab: Novartis

  • Cemiplimab (Libtayo)- Regeneron Pharmaceuticals/Sanofi

Request for sample pages: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight

Table of contents:

  1. Introduction

  2. Executive Summary

  3. Non-Small Cell Lung Cancer: Overview

  4. Pipeline Therapeutics

  5. Therapeutic Assessment

  6. Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

  7. In-depth Commercial Assessment

  8. Non-Small Cell Lung Cancer Collaboration Deals

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.